---
title: "12 Health Care Stocks Moving In Wednesday's Pre-Market Session"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/302561852.md"
description: "During Wednesday's pre-market session, several healthcare stocks showed significant movement. Pharvaris (PHVS) surged 19.4% to $36.9, while CalciMedica (CALC) rose 13.14%. Other gainers included Roivant Sciences, Stablecoin Development, Tonix Pharmaceuticals, and Advanced Biomed. Conversely, Alpha Teknova (TKNO) plummeted 29.4%, followed by declines in IRulya Therapeutics, SCWorx, Accendra Health, CytoSorbents, and Xtant Medical Holdings."
datetime: "2026-10-21T12:05:35.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/302561852.md)
  - [en](https://longbridge.com/en/news/302561852.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/302561852.md)
generator: "portal-rs"
---

# 12 Health Care Stocks Moving In Wednesday's Pre-Market Session

### Gainers

-   **Pharvaris** (NASDAQ:PHVS) stock moved upwards by 19.4% to $36.9 during Wednesday's pre-market session. The market value of their outstanding shares is at $2.0 billion.
-   **CalciMedica** (NASDAQ:CALC) shares rose 13.14% to $1.21. The company's market cap stands at $6.9 million.
-   **Roivant Sciences** (NASDAQ:ROIV) shares moved upwards by 9.59% to $38.27. The market value of their outstanding shares is at $25.0 billion.
-   **Stablecoin Development** (AMEX:SDEV) stock rose 8.68% to $0.9. The company's market cap stands at $22.7 million.
-   **Tonix Pharmaceuticals** (NASDAQ:TNXP) shares moved upwards by 8.65% to $6.28. The company's market cap stands at $98.2 million.
-   **Advanced Biomed** (NASDAQ:ADVB) shares increased by 8.42% to $4.12. The company's market cap stands at $6.7 million.

### Losers

-   **Alpha Teknova** (NASDAQ:TKNO) stock declined by 29.4% to $5.22 during Wednesday's pre-market session. The company's market cap stands at $365.0 million.
-   **IRulya Therapeutics** (NASDAQ:IRLA) stock decreased by 19.13% to $32.57. The market value of their outstanding shares is at $35.0 million.
-   **SCWorx** (NASDAQ:WORX) shares decreased by 11.19% to $3.25.
-   **Accendra Health** (NYSE:ACH) stock declined by 9.95% to $0.23. The market value of their outstanding shares is at $16.8 million.
-   **CytoSorbents** (NASDAQ:CTSO) shares fell 9.78% to $4.8. The market value of their outstanding shares is at $15.6 million.
-   **Xtant Medical Holdings** (AMEX:XTNT) stock decreased by 7.03% to $0.28. The market value of their outstanding shares is at $40.8 million. **See Also:** www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

### Related Stocks

- [ACH.US](https://longbridge.com/en/quote/ACH.US.md)
- [ADVB.US](https://longbridge.com/en/quote/ADVB.US.md)
- [CALC.US](https://longbridge.com/en/quote/CALC.US.md)
- [CTSO.US](https://longbridge.com/en/quote/CTSO.US.md)
- [IRLA.US](https://longbridge.com/en/quote/IRLA.US.md)
- [NBY.US](https://longbridge.com/en/quote/NBY.US.md)
- [OMI.US](https://longbridge.com/en/quote/OMI.US.md)
- [PHVS.US](https://longbridge.com/en/quote/PHVS.US.md)
- [QNCX.US](https://longbridge.com/en/quote/QNCX.US.md)
- [ROIV.US](https://longbridge.com/en/quote/ROIV.US.md)
- [SDEV.US](https://longbridge.com/en/quote/SDEV.US.md)
- [TKNO.US](https://longbridge.com/en/quote/TKNO.US.md)
- [TNXP.US](https://longbridge.com/en/quote/TNXP.US.md)
- [WORX.US](https://longbridge.com/en/quote/WORX.US.md)
- [XTNT.US](https://longbridge.com/en/quote/XTNT.US.md)

## Related News & Research

- [How Investors May Respond To Roivant Sciences (ROIV) Phase 3 Uveitis Win](https://longbridge.com/en/news/302884227.md)
- [Roivant to seek label expansion for Lisraya in uveitis after late-stage trial win](https://longbridge.com/en/news/302572525.md)
- [Two Pills, One Target: Analyst Bets on Pharvaris as Clinical Risks Fade](https://longbridge.com/en/news/302917214.md)
- [Roivant President and Immunovant CEO Eric Venker reports sale of $7.02 million in Roivant common shares](https://longbridge.com/en/news/302786258.md)
- [Roivant's Brepocitinib Meets Primary Endpoint in Both Phase 3 Uveitis Trials](https://longbridge.com/en/news/302551057.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**